Physician profile
Mohammad Tariq
NPI 1386792521
$1,594.80
in general payments reported to CMS, 2019-2025
20 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $125 · 2021: $11.56 · 2022: $343 · 2023: $232 · 2024: $458 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $274.23 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.85 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $161.84 | 2020-2024 | Airsupra, Breztri, Tezspire |
| Abbvie INC. | $157.08 | 2023-2025 | Avycaz |
| Actelion Pharmaceuticals US, INC. | $109.72 | 2022-2024 | Uptravi, Opsumit |
| Grifols USA, LLC | $97.71 | 2022-2024 | Prolastin-C Liquid |
| Electromed, INC. | $94.33 | 2022-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $69.95 | 2024 | Dupixent |
| Pfizer INC. | $59.84 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $53.85 | 2024 | Acthar |
| Advanced Respiratory, INC | $49.15 | 2019 | |
| Genentech USA, INC. | $47.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $32.66 | 2022 | |
| Pulmonx Corporation | $30.19 | 2023-2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Novartis Pharmaceuticals Corporation | $20.72 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20.18 | 2020 | |
| Amgen INC. | $19.89 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $19.52 | 2023 | Glassia |
| Genzyme Corporation | $15.49 | 2022 | |
| Mylan Specialty L.P. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Tariq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.